181 related articles for article (PubMed ID: 12930146)
1. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
4. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
5. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
6. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
7. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
[TBL] [Abstract][Full Text] [Related]
8. 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.
Zhang YM; Fan X; Chakaravarty D; Xiang B; Scannevin RH; Huang Z; Ma J; Burke SL; Karnachi P; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):409-13. PubMed ID: 17981034
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
10. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
[TBL] [Abstract][Full Text] [Related]
11. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
14. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
[No Abstract] [Full Text] [Related]
15. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
Brockunier LL; He J; Colwell LF; Habulihaz B; He H; Leiting B; Lyons KA; Marsilio F; Patel RA; Teffera Y; Wu JK; Thornberry NA; Weber AE; Parmee ER
Bioorg Med Chem Lett; 2004 Sep; 14(18):4763-6. PubMed ID: 15324904
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
17. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
18. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
[TBL] [Abstract][Full Text] [Related]
19. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.
Thorstensson F; Wångsell F; Kvarnström I; Vrang L; Hamelink E; Jansson K; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2007 Jan; 15(2):827-38. PubMed ID: 17107807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
